Santhera Pharmaceuticals AG licensed European rights to idebenone in Duchenne muscular dystrophy (DMD) to Takeda Pharmaceutical Co. Ltd., in return for an up-front payment of €2 million, another €18 million (US$24.6 million) in milestones and royalties on eventual product sales. (BioWorld International)
Trion Pharma GmbH and its partner Fresenius Biotech GmbH remain on track to file for approval in Europe this year for their 'trifunctional antibody' removab (catumaxomab), which attained the primary endpoint and several secondary endpoints in a Phase II/III clinical trial in advanced cancer patients with malignant ascites. (BioWorld International)
Trion Pharma GmbH and its partner Fresenius Biotech GmbH remain on track to file for approval in Europe this year for their 'trifunctional antibody' removab (catumaxomab), which attained the primary endpoint and several secondary endpoints in a Phase II/III clinical trial in advanced cancer patients with malignant ascites. (BioWorld International)
Arpida AG remains on track to file for marketing approval for the intravenous antibiotic iclaprim in the U.S. and Europe before the year-end, following positive topline data from a second pivotal trial of the compound in patients with complicated skin and skin structure infection (cSSSI). (BioWorld International)
